原始来源记录
决策级顶线结果
Neurogene 公布 NGN-401 在 Rett 综合征中的 1/2 期积极数据
该 8-K 文件披露 Neurogene 发布了其 NGN-401 基因疗法在 Rett 综合征女性患者中的 1/2 期试验更新积极临床数据。公司同日还举办了电话会议，并发布了企业演示材料。备案文件中未提及未来的监管里程碑日期。
关键事实
来源摘录
ngne-20260629 0001404644 FALSE 0001404644 2024-03-18 2024-03-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 29, 2026 Neurogene Inc. (Exact name of registrant as specified in its charter) Delaware 001-36327 98-0542593 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 535 W 24 th Street , 5 th Floor New York , NY 10011 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: ( 877 ) 237-5020 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate bo